Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib, Capecitabine, and Irinotecan in Metastatic Colorectal Cancer
NCT00230399Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2003
- Primary completion
- Jan 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in colorectal cancer (metastatic) (mCRC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Objective Response Rate. Started Jun 2003; status: completed.
02
Drugs
celecoxib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00230399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230399.